Smith and Nephew's house broker counts cost of Dermagraft:
This article was originally published in Clinica
Executive Summary
Smith & Nephew shares fell to a three-year low, after its house broker, Dresdner Kleinwort Benson, forecast profits for the London-based company of £68 million ($109 million) in the half-year to June, down from £81 million the previous year. S&N committed $35 million to Advanced Tissue Sciences, its partner for the artificial skin product, Dermagraft, in January, but the FDA says a new clinical trial is needed before the product can be approved for diabetic foot ulcers (see Clinica Nos 812, p 14 & 792, p 9). In addition, S&N has seen the strong value of sterling and the US dollar affect its profits over the past 18 months.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.